Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Scores Clinical Win In Sixth Disease For Dupixent

First Biologic To Reduce Itch And Skin Lesions From Prurigo Nodularis

Executive Summary

The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.

You may also be interested in...



Dupixent Keeps Sanofi At Forefront Of European Pharma Growth

Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.

Sanofi/Regeneron’s Esophagitis Data Add To Dupixent’s Winning Streak

The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.

FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel